INVO Bioscience, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (trading symbol: INVO) on September 7, 2021, reporting events occurring on September 1, 2021. The filing details the consummation of an acquisition intended to accelerate the company's expansion of its INVO Center clinic model into the Canadian marketplace.
Key Financial Metrics and Transaction Details
The filing reports a specific asset acquisition rather than standard periodic financial results (revenue, profit, or cash flow). The financial terms of the acquisition of Effortless IVF Canada, Inc. are as follows:
- Cash Consideration: $25,000 paid at closing.
- Equity Consideration: 30,000 shares of INVO common stock issued immediately.
- Legal Cost Reimbursement: Up to $4,000 to target shareholders.
- Debt and Liquidity: The filing text does not provide a clear value for the company's overall debt, liquidity, or cash flow position outside of the specific transaction costs.
Material Changes and Earn-Out Provisions
The primary material change is the acquisition of Effortless IVF Canada, Inc., which will be renamed "INVO Canada." The transaction includes a significant contingent earn-out provision:
- Earn-Out Structure: Up to 60,000 additional shares of common stock may be issued.
- Trigger: 20,000 shares per clinic established and operational performing the INVO procedure.
- Limit: Capped at 3 clinics.
- Timeline: Must be achieved within 24 months of closing (by August 31, 2023).
- Criteria: Target shareholders must provide support including initial clinic introduction, start-up support, and technology education.
Outlook, Risks, and Management Commentary
Management states the acquisition is designed to replicate the company's successful U.S. market approach in Canada. The target entity had already developed necessary procedures and documentation for clinical operations under Canadian regulations. The issuance of shares was conducted under the exemption from registration provided by Regulation S of the Securities Act of 1933. The filing does not explicitly list new risks or contingencies beyond the standard operational risks associated with establishing new clinics.
Key Facts for Investor Verification
- Verify the total number of shares issued (30,000 immediate + potential 60,000 earn-out) against the company's current authorized share count and dilution impact.
- Confirm the operational status of the acquired entity and the timeline for establishing the first Canadian clinic to trigger earn-out shares.
- Review the full Share Purchase Agreement (Exhibit 10.1) for additional covenants or restrictions not detailed in the summary.
- Monitor future filings for the actual cash outflow impact of the $25,000 purchase price and legal reimbursements on the company's balance sheet.